Table 6.
Hyperoxia mdx Hemodynamic Data.
| Baseline | Dobutamine | Esmolol | Significance | |
|---|---|---|---|---|
| Heart Rate (bpm) | 490 ± 17.2 (8) | 562 ± 6.9 (8) | 399 ± 10.2 (8) | b,c |
| End-Systolic Pressure (mmHg) | 93.1 ± 2.19 (8) | 104 ± 2.59 (8) | 69.7 ± 6.11 (8) | c,d |
| End-Diastolic Pressure (mmHg) | 8.84 ± 1.22 (8) | 8.61 ± 1.02 (8) | 10.3 ± 0.771 (8) | |
| Maximum dP/dt (mmHg/s) | 8478 ± 464 (8) | 13460 ± 303 (8) | 3974 ± 479 (8) | a,b,d |
| Minimum dP/dt (mmHg/s) | 8402 ± 389 (8) | 9418 ± 292 (8) | 4464 ± 688 (8) | b,c,d |
| Tau (msec) | 7.23 ± 0.61 (8) | 6.5 ± 0.691 (8) | 15.3 ± 3.9 (8) | |
| End-Diastolic Volume (μl) | 38.6 ± 3.19 (8) | 37.7 ± 4.93 (8) | 50.1 ± 5.1 (8) | |
| End-Systolic Volume (μl) | 25.4 ± 2.29 (8) | 17.5 ± 1.52 (8) | 41.2 ± 5.2 (8) | |
| Cardiac Output (μl/min) | 9738 ± 749 (8) | 14288 ± 3075 (8) | 7382 ± 2017 (8) | |
| PRSW (mmHg⋅μl/μl) | 66.1 ± 3.38 (8) | 85.4 ± 3.63 (8) | 40.3 ± 7.45 (8) |
Significant testing by three-way ANOVA with genotype, oxygen therapy protocol, and hemodynamic protocol treatment as factors with Tukey post-hoc test. a; signifies difference between baseline and dobutamine with hyperoxic protocol in mdx mice; b: signifies difference between baseline and esmolol with hyperoxic treatment in mdx mice; c: signifies an overall genotype effect; d: represents an overall difference between hyperoxia and normoxic treatment; e: represents an overall difference between HBOT and hyperoxic treatment.